References

  1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr: Efficacy and safety of recombinant human activated protein C for severe sepsis.

    N Engl J Med 2001, 344:699-709. PubMed Abstract | Publisher Full Text OpenURL

  2. US Food and Drug Administration: Drotrecogin alfa (activated), Xigris, BLA #125029/0. FDA Briefing Information. [http://www.fda.gov/cber/label/droteli112101LB.pdf]

    US Food and Drug Administration OpenURL

    6 August 2001

  3. US Food and Drug Administration: Drotrecogin alfa (activated), Xigris, BLA #125029/0. FDA Briefing Information. [http://www.fda.gov/cber/label/droteli112101r1.pdf]

    US Food and Drug Administration OpenURL

  4. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system.

    Crit Care Med 1985, 13:818-829. PubMed Abstract OpenURL

  5. European Agency for the Evaluation of Medicinal Products (EMEA): European Public Assessment Report [EPAR] Xigris. [http://www.eudra.org/humandocs/Humans/EPAR/xigris/xigris.htm]

    European Agency for the Evaluation of Medicinal Products OpenURL

    17 Oct 2002

  6. Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

    Intens Care Med 2003, 29:894-903. OpenURL

  7. Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

    Crit Care Med 2003, 31:12-19. PubMed Abstract | Publisher Full Text OpenURL

  8. Esmon CT: The protein C anticoagulation pathway.

    Arterioscler Thromb 1992, 12:135-145. PubMed Abstract OpenURL

  9. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W: Activation of endothelial cell protease activated receptor 1 by the protein C pathway.

    Science 2002, 296:1880-1882. PubMed Abstract | Publisher Full Text OpenURL

  10. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW: Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis.

    J Biol Chem 2001, 276:11199-11203. PubMed Abstract | Publisher Full Text OpenURL

  11. Schein RMH, Kinasewitz GT: Risk-benefit analysis for drotrecogin alfa (activated).

    Am J Surg 2002, 184(suppl):25S-38S. Publisher Full Text OpenURL

  12. Bernard G, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL: Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

    Crit Care 2003, 7:155-163. PubMed Abstract | BioMed Central Full Text | PubMed Central Full Text OpenURL

  13. Oppenheim-Eden A, Glantz L, Eidelman LA, Sprung CL: Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors.

    Intens Care Med 1999, 25:63-67. Publisher Full Text OpenURL

  14. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM: Caring for the critically ill patient: high-dose antithrombin III in severe sepsis:a randomized controlled trial.

    JAMA 2001, 286:1869-1878. PubMed Abstract | Publisher Full Text OpenURL

  15. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P: Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland.

    Arch Intern Med 2000, 160:2781-2787. PubMed Abstract | Publisher Full Text OpenURL

  16. Cabell CH, Pond KK, Peterson GE, Durack DT, Corey GR, Anderson DJ, Ryan T, Lukes AS, Sexton DJ: The risk of stroke and death in patients with aortic and mitral valve endocarditis.

    Am Heart J 2001, 142:75-80. PubMed Abstract | Publisher Full Text OpenURL

  17. Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G 3rd, Small DS: Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.

    Clin Pharmacol Ther 2002, 72:391-402. PubMed Abstract | Publisher Full Text OpenURL

  18. Laterre PF, Heiselman D: Management of patients with severe sepsis, treated by drotrecogin alfa (activated).

    Am J Surg 2002, 184(suppl):39S-46S. Publisher Full Text OpenURL

  19. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and laboratory criteria, and scoring system for disseminated intravascular coagulation.

    Thromb Haemost 2001, 86:1327-1330. PubMed Abstract OpenURL